Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rani Therapeutics Holdings Inc (RANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RANI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.75
1 Year Target Price $7.75
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.97% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.12M USD | Price to earnings Ratio - | 1Y Target Price 7.75 |
Price to earnings Ratio - | 1Y Target Price 7.75 | ||
Volume (30-day avg) 4 | Beta -0.01 | 52 Weeks Range 0.39 - 3.34 | Updated Date 08/29/2025 |
52 Weeks Range 0.39 - 3.34 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.29 | Actual -0.18 |
Profitability
Profit Margin - | Operating Margin (TTM) -3796.75% |
Management Effectiveness
Return on Assets (TTM) -93.94% | Return on Equity (TTM) -1187.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37256463 | Price to Sales(TTM) 34.27 |
Enterprise Value 37256463 | Price to Sales(TTM) 34.27 | ||
Enterprise Value to Revenue 31.05 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 47898200 | Shares Floating 33616892 |
Shares Outstanding 47898200 | Shares Floating 33616892 | ||
Percent Insiders 19.56 | Percent Institutions 17 |
Upturn AI SWOT
Rani Therapeutics Holdings Inc
Company Overview
History and Background
Rani Therapeutics Holdings, Inc. was founded in 2012 and is a clinical-stage biotherapeutics company advancing an innovative platform for the oral delivery of biologics, the RaniPill capsule. They are working to transform the treatment of chronic diseases by replacing injections with pills.
Core Business Areas
- RaniPill Development: Focuses on the development and commercialization of the RaniPill capsule, a novel drug delivery platform designed to orally administer biologics and other drugs traditionally given by injection.
Leadership and Structure
Mir Imran serves as Chairman, and Talat Imran is the CEO. The company is structured around research and development, clinical trials, and manufacturing to support the RaniPill platform.
Top Products and Market Share
Key Offerings
- RaniPill Capsule: The RaniPill capsule is the company's primary product, an orally administered capsule designed to deliver biologics and other drugs typically given by injection. Rani Therapeutics is currently running clinical trials with no approved products currently on the market. Competitors are traditional injectable biologics and other oral drug delivery systems under development by other companies (e.g., Novo Nordisk, Eli Lilly).
Market Dynamics
Industry Overview
The pharmaceutical industry is increasingly focused on developing and improving drug delivery methods, particularly for biologics. Oral delivery of biologics is a significant unmet need.
Positioning
Rani Therapeutics is positioned as an innovator in oral biologics delivery, potentially disrupting the traditional injectable market. However, they are still in the clinical stage and face significant regulatory and market access hurdles.
Total Addressable Market (TAM)
The TAM for injectable biologics is vast, estimated in the hundreds of billions of dollars globally. Rani Therapeutics' TAM is the portion of this market that can be converted to oral administration via the RaniPill, which is still uncertain but potentially large if successful.
Upturn SWOT Analysis
Strengths
- Innovative RaniPill technology
- Potential to replace injections with oral pills
- Focus on biologics delivery
Weaknesses
- Clinical stage company with no approved products
- High development costs and regulatory risks
- Reliance on successful clinical trial outcomes
Opportunities
- Partnerships with pharmaceutical companies
- Expansion to new therapeutic areas
- Positive clinical trial results driving market interest
Threats
- Competition from existing injectable biologics
- Regulatory hurdles and delays
- Clinical trial failures
- Other competing drug delivery platforms
Competitors and Market Share
Key Competitors
- NVO
- LLY
- VTRS
- SNY
Competitive Landscape
Rani Therapeutics' key advantage is its innovative oral delivery platform. However, they face competition from established pharmaceutical companies with approved injectable biologics and other drug delivery technologies.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by progress in clinical trials and partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst projections vary widely given the uncertainty.
Recent Initiatives: Recent initiatives include advancing clinical trials for various therapeutic areas and securing partnerships with pharmaceutical companies.
Summary
Rani Therapeutics is an innovative company developing a novel oral drug delivery platform, the RaniPill. Its success depends on positive clinical trial outcomes and regulatory approvals. The company currently operates at a loss and faces competition from established pharmaceutical companies. While the technology shows promise, significant risks remain regarding clinical trial success and market adoption.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Rani Therapeutics' website
- SEC filings (10-K, 10-Q reports)
- Analyst reports
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate and may vary based on source and methodology. Future performance is not guaranteed and is subject to numerous risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rani Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-07-30 | CEO & Director Mr. Talat Imran | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.ranitherapeutics.com |
Full time employees 105 | Website https://www.ranitherapeutics.com | ||
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.